Peak Bio, Inc. (PKBO)
Peak Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Palo Alto, CA, US. The stock last traded at $0.02, giving a market capitalisation of $520,310. On trailing twelve-month figures it carries a trailing P/E of -3.13, a net margin of 0.0%. Its beta of 1.78 implies it has historically moved more than the broad market.
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Peak Bio, Inc. is most often compared with the following Healthcare names: